Diabetic Retinopathy Market By Type (NPDR, PDR); By Treatment Modality (Anti-VEGF Therapy, Corticosteroid Implants, Laser Photocoagulation, Vitrectomy, Others); By End User (Hospitals, Ophthalmic Clinics, ASCs, Diagnostic Imaging Centers); By Geography, Segment Revenue Estimation, Forecast, 2024–2030.

Introduction and Strategic Context

The Global Diabetic Retinopathy Market is projected to grow at a robust CAGR of 7.6%, with a base valuation of $8.9 billion in 2024, and is expected to reach approximately $13.9 billion by 2030, according to Strategic Market Research.

Diabetic retinopathy (DR) is a progressive eye condition that affects the blood vessels in the retina and is a leading cause of blindness in adults with diabetes. As of 2024, an estimated 537 million adults globally are living with diabetes—a figure projected to exceed 640 million by 2030—making diabetic eye complications a critical public health challenge. The strategic importance of the diabetic retinopathy market stems from the global rise in diabetes prevalence, increasing geriatric population, advancements in diagnostic imaging, and proactive screening initiatives.

From a technology standpoint, AI-enabled diagnostic platforms, OCT angiography, and teleophthalmology are redefining early detection and care pathways. Automated grading algorithms and cloud-based image sharing tools are becoming essential for scalable screening models, particularly in under-resourced regions. Moreover, governments and private health systems are investing heavily in population-based diabetic eye screening programs, especially across Europe, the U.S., and India.

In regulatory terms, fast-track designations and reimbursement coverage for anti-VEGF therapies, corticosteroid implants, and laser photocoagulation are fueling both innovation and access. The rising burden of vision-threatening DR and diabetic macular edema (DME) has also spurred interest from ophthalmology-focused pharmaceutical companies and device OEMs.

Key market stakeholders include:

• Pharmaceutical companies (e.g., Genentech, Regeneron, Allergan)
• Medical device manufacturers (e.g., Carl Zeiss Meditec, Topcon, Heidelberg Engineering)
• Healthcare providers and hospitals
• Telemedicine and AI platform developers
• Government and public health agencies
• Research institutions and universities
• Investors and venture capital firms focused on digital health and ophthalmology

Strategically, the diabetic retinopathy market sits at the intersection of chronic disease management, precision diagnostics, and digital health transformation. With clinical pathways increasingly shifting toward preventive and personalized eye care, DR detection and management solutions are poised to serve as anchor points in next-generation diabetic health ecosystems.

The expansion is underpinned by the surging diabetes burden worldwide, accelerated adoption of anti-VEGF and sustained-release biologics, and the proliferation of national screening initiatives integrating AI-enabled retinal imaging and tele-ophthalmology.

 

The United States remains the largest single market, valued at USD 3.72 billion in 2024, projected to reach USD 5.64 billion by 2030 (CAGR 6.8%), driven by high diagnosis and treatment penetration, advanced reimbursement frameworks, and rapid uptake of extended-interval biologic therapies. Europe, valued at USD 2.66 billion in 2024, will rise to USD 3.68 billion by 2030 (CAGR 5.7%) as biosimilars and standardized screening pathways mature under national health systems. The Asia-Pacific (APAC) region, valued at USD 1.8 billion in 2024, is projected to grow fastest, touching USD 2.87 billion by 2030 (CAGR 8.2%), driven by large unmet clinical needs, expanding diabetic populations, and increasing investments in affordable screening and care access.

 

Globally, diabetic retinopathy affects approximately 103 million adults, a figure expected to rise to over 160 million by 2045 according to the International Diabetes Federation (IDF). In the United States alone, 9.6 million individuals (26.4% of all diabetics) had DR as of 2021. In Europe, recent population studies suggest prevalence around 20–21% of diabetic adults, while Asia’s regional average remains ~12–22%.

 

Diabetic Retinopathy Market Dynamics

Key Growth Drivers

1. Rising Global Diabetes Burden — The IDF projects 783 million people with diabetes by 2045. Given that roughly one in four develops DR, the addressable population for diagnostic and therapeutic intervention is escalating rapidly.

2. Adoption of Advanced Therapeutics — Anti-VEGF agents (Eylea®, Lucentis®, Vabysmo®) and sustained-release port-delivery implants (Susvimo®) have transformed treatment paradigms, enhancing visual outcomes and reducing injection frequency.

3. Expansion of AI-Based Screening — FDA-cleared AI platforms for autonomous DR detection (IDx-DR, Eyenuk EyeArt) are being integrated into primary-care networks, increasing early detection and therapy uptake.

4. Public Health Screening Initiatives — Government-funded programs like the UK NHS Diabetic Eye Screening Programme and India’s National Programme for Control of Blindness are enhancing screening rates.

 

Market Restraints

• Uneven Access and Screening Coverage: CDC data show that only ~60–65% of U.S. adults with diabetes receive recommended annual retinal exams; coverage drops below 40% in low- and middle-income countries.

• High Therapy Costs: Anti-VEGF injections cost USD 1,500–2,000 per dose in high-income markets, posing reimbursement challenges and limiting adherence.

• Infrastructure Gaps: In APAC and emerging regions, shortages of ophthalmologists and diagnostic equipment constrain scalable screening coverage.

 

Technological & Clinical Trends

• AI-Enabled Diagnostic Platforms: Autonomous AI systems for DR detection now approved by FDA and CE marking (Eyenuk, IDx DR), expanding access in primary care settings.

• Next-Generation Therapeutics: Dual VEGF/Ang-2 inhibitors such as Faricimab (Vabysmo®) and long-acting delivery systems are reducing treatment burden.

• Wide-Field and OCT-A Imaging: Increasing adoption in clinical settings to quantify non-perfusion and microvascular changes for precision staging.

• Tele-Retinal and Home-Monitoring: Integration of portable fundus cameras and cloud-based grading systems facilitates continuous disease tracking in rural and underserved regions.

 

Regional Insights (United States, Europe & APAC)

United States

The U.S. represents the most mature DR market, supported by a comprehensive screening ecosystem and rapid uptake of innovative biologics. As of 2021, 9.6 million Americans (26.4% of people with diabetes) were living with DR, and 1.84 million (5.1%) had vision-threatening disease. The availability of AI diagnostics under Medicare, together with new anti-VEGF biosimilars and durable implants, is propelling treatment volumes. Market value is forecast to grow from USD 3.72 billion (2024) to USD 5.64 billion (2030) (CAGR 6.8%).

 

Europe

European markets are characterized by strong screening programmes and broad public-payer coverage. A 2024 multinational meta-analysis placed DR prevalence among diabetics at ~20.6%. Uptake of anti-VEGF biosimilars and compliance with EU Medical Device Regulation (MDR) continue to shape product access. Regional market value is expected to rise from USD 2.66 billion (2024) to USD 3.68 billion (2030) (CAGR 5.7%).

 

Asia-Pacific (APAC)

APAC exhibits the highest growth potential, with rapid urbanization and dietary transitions driving an epidemic of type 2 diabetes. DR prevalence ranges from 12% to 22% across the region. India reports ~16.9% of diabetic adults with DR and 3.6% with sight-threatening disease. The region is experiencing surging investments in low-cost fundus imaging, AI-based screening, and affordable biosimilar therapies. Market value is projected to rise from USD 1.8 billion (2024) to USD 2.87 billion (2030) (CAGR 8.2%).

 

Segmental Landscape

Segment	Key Highlights (2024–2030)
By Stage	Non-Proliferative DR (NPDR) dominates case load (~70% of diagnosed patients), while Proliferative DR (PDR) drives ~45–50% of treatment spend.
By Treatment Type	Anti-VEGF injections remain first-line; laser photocoagulation and vitrectomy retain role in advanced stages. Emerging sustained-release implants and dual-pathway biologics extend treatment durability.
By End User	Hospitals and ophthalmology clinics dominate procedures; ambulatory surgery centres (ASCs) gain share in outpatient injections; diagnostic centres expand screening reach via tele-ophthalmology.

 

Investment & Future Outlook

Public-private investments in AI diagnostics and digital ophthalmology are escalating globally. Funding for machine-learning-based retinal analytics and portable imaging devices is expected to grow > 20% annually through 2028. Additionally, value-based care frameworks linking outcomes to reimbursement are encouraging providers to prioritize early screening and long-acting therapies. In APAC, government-led screening campaigns and domestic biosimilar production are creating a competitive yet high-volume market environment.

 

R&D and Regulatory Developments

• FDA Approvals (2024–2025): Vabysmo® prefilled syringe for DME/DR (July 2024); Susvimo® ranibizumab implant for DR (May 2025).

• EMA & PMDA Alignments: Vabysmo and Eylea HD approved across EU and Japan for DR and DME indications.

• Clinical Trials: Over 120 active phase II–III studies globally evaluating novel biologics, gene therapies, and AI decision-support tools.

 

Strategic Landscape & Partnerships

• Pharma–Device Alliances: Ongoing collaborations between biologic manufacturers and imaging/AI companies to integrate screening-to-therapy pathways.

• Biosimilar Expansion: European and Indian biosimilar approvals expected to significantly reduce therapy costs and broaden access.

• Digital Ophthalmology Initiatives: Partnerships between national health systems and AI platforms (IDx-DR, Eyenuk) to meet population-screening targets.

 

Strategic Recommendations for Industry Leaders

1. Integrate Screening & Therapy: Develop vertically linked solutions combining AI diagnostics with biologic delivery to capture the full patient journey.

2. Localize Access Models: In APAC and Latin America, deploy low-cost screening units and tiered therapy pricing to expand reach.

3. Leverage Biosimilars: In Europe, use biosimilar portfolio synergies to capture share from originators while maintaining margin through service integration.

4. Invest in Durability: Prioritize R&D in sustained-release delivery and combination mechanisms (VEGF + Ang-2 or VEGF + PDGF) to reduce treatment burden.

5. Engage Policy Frameworks: Align with government screening initiatives and value-based care pilots to secure early reimbursement inclusion.

 

Strategic Highlights & C-Suite Takeaways

• USD 8.9 → 13.9 Billion (2024–2030): Global market expanding at 7.6% CAGR, driven by rising diabetes burden and AI-based screening uptake.

• Regional Momentum: U.S. USD 3.72 → 5.64 B (CAGR 6.8%); Europe USD 2.66 → 3.68 B (CAGR 5.7%); APAC USD 1.8 → 2.87 B (CAGR 8.2%).

• Therapeutic Shift: Durable delivery biologics and biosimilars to reshape therapy economics by 2026+.

• Digital Acceleration: AI-screening integration across U.S., EU, and India drives earlier diagnosis and market expansion.

• Investment Priority: Stake in AI diagnostics, extended-interval biologics, and real-world evidence infrastructure to capture next-generation growth.

 

The diabetic retinopathy market is transitioning from a reactive to a preventive-integrated care model. With the global burden of diabetes accelerating and vision loss prevention gaining policy priority, the DR market is poised for sustained expansion. The period through 2030 will redefine competitive advantage — favouring companies that combine technological innovation, affordability, and health-system integration to deliver scalable, equitable retinal care.

 

2. Market Segmentation and Forecast Scope

The global diabetic retinopathy market is segmented based on type, treatment modality, end user, and geography. This segmentation framework allows a granular understanding of commercial dynamics, innovation potential, and patient adoption trends across healthcare ecosystems.

By Type

• Non-proliferative diabetic retinopathy (NPDR)
• Proliferative diabetic retinopathy (PDR)

NPDR represents the dominant share of over 62% in 2024, primarily due to higher incidence during early-stage screenings. However, PDR is projected to be the fastest-growing subtype, driven by rising diagnoses of advanced diabetes in middle- and low-income countries where primary care gaps delay early detection.

By Treatment Modality

• Anti-VEGF therapy
• Corticosteroid implants
• Laser photocoagulation
• Vitrectomy
• Others (e.g., lifestyle and blood sugar control)

Anti-VEGF therapy currently leads this segment, benefiting from high clinical efficacy and broad insurance coverage. Real-world evidence supports its use in both NPDR and DME, and the introduction of longer-acting formulations is expanding patient convenience.

By End User

• Hospitals
• Ophthalmic clinics
• Ambulatory surgical centers (ASCs)
• Diagnostic imaging centers

Hospitals account for the largest market share due to their capacity for multi-modality treatment, emergency retinal care, and access to retinal specialists. However, diagnostic imaging centers are emerging as strategic growth points with the rise of AI-enabled remote screening and tele-ophthalmology programs.

By Geography

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa

North America remains the revenue leader in 2024, accounting for nearly 40% of the global market, backed by sophisticated diagnostic infrastructure and high diabetes awareness. However, Asia Pacific is forecasted to grow at the fastest CAGR of 9.3%, fueled by escalating diabetic populations in India and China, government screening programs, and increased accessibility to anti-VEGF biosimilars.

Strategically, emerging regions with underserved diabetic populations present vast white space opportunities for market players focused on digital diagnostics, mobile health, and AI.

3. Market Trends and Innovation Landscape

The diabetic retinopathy market is undergoing a transformative shift as new technologies converge with clinical and public health imperatives. Key trends shaping the innovation landscape from 2024 to 2030 include advancements in AI-driven diagnostics, long-acting therapeutics, minimally invasive procedures, and integrated teleophthalmology ecosystems.

1. AI-Powered Screening and Diagnostics

One of the most disruptive trends is the integration of artificial intelligence (AI) in retinal image analysis. Startups and global medtech firms alike are developing FDA-cleared AI platforms capable of autonomously detecting diabetic retinopathy from fundus images with sensitivity and specificity comparable to human experts. These tools are especially valuable in rural or under-resourced areas with few ophthalmologists.

For example, primary care clinics in Southeast Asia are piloting cloud-connected AI platforms that enable same-day DR screening, dramatically reducing referral times.

2. Emergence of Long-Acting and Sustained-Release Therapies

Biopharma companies are investing in long-duration anti-VEGF therapies and intravitreal implants that reduce the injection burden for patients. Products with 3–6 month release cycles are improving adherence and outcomes. The development of biodegradable and refillable implants also represents a shift toward patient-centric design.

Moreover, biosimilars of ranibizumab and aflibercept are now entering markets across Asia, Latin America, and parts of Europe—providing cost-effective alternatives and expanding access.

3. OCT and Multimodal Imaging Enhancements

Optical coherence tomography (OCT) continues to evolve with the advent of OCT-Angiography (OCT-A), offering detailed vascular imaging without the need for contrast dyes. These systems, when integrated with AI, allow for earlier detection of subclinical changes and pre-symptomatic DR.

Leading OEMs are also combining fundus cameras, OCT, and widefield imaging into a single diagnostic unit—reducing the need for multiple patient visits.

4. Teleophthalmology Integration

With the rising use of store-and-forward telemedicine models, patients are now able to get their retinal images captured at a general physician’s office and remotely interpreted by a retinal specialist or AI system. These workflows are transforming diabetic eye care from episodic treatment to preventive population management.

In Canada, national health systems are deploying remote screening units with AI triaging in remote provinces to address specialist shortages.

5. M&A and Innovation Partnerships

Recent years have seen a flurry of collaborations between pharma, AI developers, and academic hospitals. For instance, partnerships between cloud-based retinal imaging firms and device manufacturers have accelerated the development of portable, AI-integrated imaging units suitable for mass screening.

This convergence of software, optics, and therapeutics is signaling a new era where diabetic eye disease is managed more like a chronic condition than an acute emergency.

4. Competitive Intelligence and Benchmarking

The diabetic retinopathy market is highly competitive and innovation-driven, with a mix of pharmaceutical giants, diagnostic device leaders, and health-tech disruptors shaping its evolution. Each player brings distinct competencies—ranging from novel drug delivery platforms to AI-powered diagnostics and digital screening ecosystems.

Below are the key companies influencing the global market:

Genentech (Roche Group)

A global leader in ophthalmology therapeutics, Genentech continues to dominate the anti-VEGF segment with innovations in long-acting formulations. The company has strategically invested in sustained-release drug delivery systems, including refillable ocular implants. Its vertically integrated R&D and commercialization pipelines offer significant advantages in both North America and Europe.

Regeneron Pharmaceuticals

Regeneron commands a significant share in diabetic macular edema and DR treatment through its anti-VEGF therapy, which has become a standard of care. Its aggressive life-cycle management strategy, real-world outcome trials, and new formulations for less frequent dosing have solidified its competitive position. The company also partners with AI diagnostic platforms to explore joint care models.

Allergan (An AbbVie Company)

Known for its corticosteroid implants, Allergan provides alternative or adjunct therapies to anti-VEGF injections. It differentiates through its focus on patients unresponsive to conventional treatments. Its broad ophthalmology portfolio and global distribution make it a preferred partner in Latin America and parts of Asia.

Carl Zeiss Meditec

Zeiss dominates the diagnostic imaging segment, offering state-of-the-art OCT and fundus imaging systems. The company is pioneering smart diagnostic suites that incorporate AI for image interpretation, enhancing DR detection accuracy. Its modular and interoperable platforms are favored by high-volume eye hospitals worldwide.

Topcon Corporation

Topcon blends diagnostic optics with teleophthalmology infrastructure. Its portable fundus cameras and cloud-enabled image archiving tools are ideal for remote and rural deployments. The company’s focus on mobile DR screening solutions supports population health management programs, particularly in Asia Pacific and Europe.

Heidelberg Engineering

Famous for its high-resolution imaging systems, Heidelberg offers advanced OCT-A platforms that allow detailed microvascular analysis—key for monitoring disease progression. Academic institutions and specialty clinics often prefer Heidelberg for research-grade diagnostics and early-stage trials.

Eyenuk Inc.

A leading AI firm in diabetic retinopathy diagnostics, Eyenuk develops FDA-approved autonomous screening tools that analyze retinal images without human intervention. Its solutions are gaining traction in outpatient clinics and primary care centers due to their scalability and accuracy.

5. Regional Landscape and Adoption Outlook

The adoption and growth trajectory of diabetic retinopathy (DR) solutions varies significantly by region, shaped by healthcare infrastructure, diabetes prevalence, government screening policies, and availability of advanced therapeutics. Below is a strategic analysis of the regional dynamics influencing the global DR market.

North America

North America leads the global market, accounting for approximately 40% of global revenue in 2024. This dominance is attributed to:

• High awareness and screening compliance among diabetic populations
• Strong reimbursement support for anti-VEGF therapies and OCT-based diagnostics
• Broad adoption of AI-driven diagnostic tools, especially in primary care networks

The U.S. is home to many global leaders in this space, including Regeneron, Genentech, and Eyenuk. Programs like Medicare-covered annual diabetic eye exams and teleophthalmology initiatives under the VA Health System exemplify public-private synergy.

Europe

Europe ranks second, driven by universal healthcare policies and structured DR screening programs, particularly in the UK, Germany, and the Nordic countries. The region is known for its:

• Widespread adoption of population-based DR screening
• Investment in portable diagnostic imaging
• Proactive government mandates on annual retinal exams for Type 2 diabetics

Countries such as the UK and Sweden are global pioneers in national screening protocols, while Germany and France are expanding access to intravitreal therapies. The EU’s AI and HealthTech funding initiatives further catalyze innovation in predictive analytics and screening automation.

Asia Pacific

The Asia Pacific region is projected to grow at the fastest CAGR of 9.3% through 2030. Key growth drivers include:

• Explosive rise in diabetes cases in India, China, and Indonesia
• Expansion of healthcare infrastructure in tier-2 and tier-3 cities
• Increased availability of biosimilars and low-cost imaging solutions

Government health programs, such as India’s NPCDCS (National Programme for Prevention and Control of Cancer, Diabetes, Cardiovascular Diseases and Stroke), now incorporate teleophthalmology pilots. Mobile screening vans equipped with AI diagnostic tools are being deployed in rural areas to boost early detection.

Latin America

Latin America presents a moderately growing market, with Brazil and Mexico as key revenue contributors. Barriers include limited specialist access and uneven diagnostic coverage. However, rising diabetic populations and partnerships with NGOs are driving grassroots screening efforts. Public-private alliances are forming to distribute low-cost retinal imaging devices in underserved urban zones.

Middle East & Africa

Although still nascent, the Middle East & Africa region shows long-term promise, particularly in the Gulf states and South Africa, where diabetic rates are climbing rapidly. Regional challenges include:

• Shortages of trained ophthalmologists
• Low screening penetration outside major cities
• High cost of anti-VEGF therapies

That said, pilot initiatives in the UAE and Saudi Arabia are integrating AI-based DR screening into national diabetes programs, signaling potential for future scale.

In summary, while North America and Europe dominate in current value, Asia Pacific and selected Middle Eastern countries are emerging as high-growth frontiers. Companies that localize their offerings—through pricing, mobile diagnostics, and AI—stand to unlock the next wave of market expansion.

6. End-User Dynamics and Use Case

The diabetic retinopathy market serves a wide spectrum of end users, each with distinct clinical requirements, care models, and technology adoption profiles. Understanding these dynamics is crucial for manufacturers and service providers targeting specific points in the diabetic eye care continuum.

Hospitals

Hospitals represent the largest and most comprehensive end-user segment. They handle high-acuity cases such as proliferative diabetic retinopathy (PDR) and diabetic macular edema (DME), offering access to:

• Advanced OCT and OCT-A imaging
• Surgical interventions like vitrectomy
• Intravitreal anti-VEGF injections

These institutions often serve as referral centers for community clinics and are early adopters of AI-enabled imaging and electronic health record (EHR) integration for tracking DR progression.

Ophthalmic Clinics

These facilities specialize in eye care and deliver both diagnostic and therapeutic services. They often operate in urban settings and are equipped with:

• Fundus photography systems
• On-site retinal specialists
• Access to both laser photocoagulation and injectable therapies

Ophthalmic clinics play a pivotal role in maintenance therapy and longitudinal DR monitoring, especially in private healthcare markets.

Ambulatory Surgical Centers (ASCs)

ASCs are increasingly performing minimally invasive eye surgeries for diabetic complications. They offer benefits such as:

• Lower procedural costs
• Reduced hospital admission times
• High throughput for elective retinal surgeries

In countries like the U.S. and South Korea, ASCs are preferred for outpatient vitrectomy and steroid implant placements, particularly among insured patients.

Diagnostic Imaging Centers

This segment is witnessing the fastest growth, thanks to the rise of:

• AI-powered DR screening platforms
• Cloud-based image sharing
• Mobile retinal imaging units

These centers cater to both walk-in diabetic patients and referrals from general practitioners. They form a bridge between primary care and specialist intervention, especially in low-resource settings.

Use Case Spotlight:

A Tertiary Hospital in South Korea Scales Early Detection Using AI-Based Imaging

In response to increasing diabetic blindness cases, a tertiary hospital in Seoul launched a digital DR screening initiative targeting newly diagnosed Type 2 diabetic patients. The hospital partnered with an AI healthtech company to deploy autonomous retinal image analysis tools across its affiliated primary care centers. Within 12 months, over 12,000 patients were screened, with a 33% increase in early-stage NPDR detection.

The program’s key outcomes included reduced wait times for ophthalmologist consults, enhanced treatment initiation for high-risk patients, and measurable cost savings by avoiding late-stage surgical interventions. Based on this success, the model is now being adapted for use in remote Korean provinces and public health clinics.

7. Recent Developments + Opportunities & Restraints

Recent Developments (2023–2025)

• FDA Approval of Eyenuk's AI Screening Tool Expansion (2023): Eyenuk received expanded FDA clearance for its EyeArt® AI system to autonomously detect both mild and moderate DR stages, making it the first AI device to cover a wider clinical spectrum in real-world settings.
• Launch of Roche's Vabysmo in Asia-Pacific Markets (2024): Roche’s dual inhibitor therapy Vabysmo, initially approved for AMD, expanded its indication to diabetic macular edema (DME) and launched across major Asia-Pacific countries.
• Topcon Collaborates with Microsoft Azure for Cloud Screening (2024): Topcon announced a global partnership with Microsoft to integrate its retinal imaging devices with Azure-based AI analytics, enabling population-wide DR screening programs.
• Heidelberg Engineering Launches Next-Gen OCT-A Unit (2025): Heidelberg unveiled a new OCT-A platform with enhanced deep vascular imaging for early PDR identification, targeted at academic centers and research hospitals.

Opportunities

• AI + Cloud Expansion into Underserved Markets: As teleophthalmology matures, AI-enabled, low-cost screening tools can bridge the specialist gap in regions with large diabetic populations but limited infrastructure (e.g., Sub-Saharan Africa, South Asia).
• Biosimilars Driving Cost Accessibility: The entry of anti-VEGF biosimilars is lowering treatment costs and expanding access to previously underpenetrated markets. Emerging economies stand to benefit significantly from affordable therapeutic options.
• Government-Led Screening Mandates: Countries like the UK, India, and Brazil are either piloting or scaling mandatory annual DR screenings, which will drive diagnostic imaging volume and service demand across public and private sectors.

Restraints

• High Cost of Intravitreal Therapies: Despite increasing biosimilar availability, many first-line anti-VEGF and corticosteroid injections remain prohibitively expensive, limiting adoption in low-income populations without insurance support.
• Shortage of Trained Retinal Specialists: Specialist bottlenecks remain a critical barrier, particularly in rural areas and developing regions where early detection is essential to avoid late-stage complications.

Report Coverage Table

Report Attribute	Details
Forecast Period	2024 – 2030
Market Size Value in 2024	USD 8.9 Billion
Revenue Forecast in 2030	USD 13.9 Billion
Overall Growth Rate	CAGR of 7.6% (2024 – 2030)
Base Year for Estimation	2023
Historical Data	2017 – 2021
Unit	USD Million, CAGR (2024 – 2030)
Segmentation	By Type, By Treatment Modality, By End User, By Geography
By Type	NPDR, PDR
By Treatment Modality	Anti-VEGF Therapy, Corticosteroid Implants, Laser Photocoagulation, Vitrectomy, Others
By End User	Hospitals, Ophthalmic Clinics, ASCs, Diagnostic Imaging Centers
By Region	North America, Europe, Asia-Pacific, Latin America, Middle East & Africa
Country Scope	U.S., UK, Germany, China, India, Japan, Brazil, South Korea, UAE
Market Drivers	AI-based screening, global diabetes prevalence, rise of biosimilars
Customization Option	Available upon request

This is the complete HTML content with all sections, headings, bullet points, and the table included as per your request